乳腺预防3乳腺癌化学预防试验中与研究治疗早期中止相关的因素
在MAP.3随机安慰剂对照试验中评估依西美坦,4501名可分析受试者中724名(17%)在随机分组后第一年内中止治疗,依西美坦组19%、安慰剂组13%;无论是否接受依西美坦,MENQOL任一领域或整体绝经特异性生活质量恶化均与早期中止治疗相关(整体恶化RR 1.79,95%CI 1.53-2.10),依西美坦分组、吸烟史和当前就业也显著相关。
要点
- MAP.3试验中17%受试者在随机后1年内中止治疗,依西美坦组19% vs 安慰剂组13%。
- 治疗6个月内19%-35%女性在MENQOL血管舒缩、性、躯体和社会心理领域出现临床有意义的恶化。
- 整体绝经特异性生活质量恶化与早期中止治疗相关(RR 1.79,95%CI 1.53-2.10)。
核心结论
- 绝经特异性生活质量的负向变化影响女性停止化学预防治疗的决定。
- 关注此类症状可能改善生活质量并可能提高化学预防依从性。
研究设计与样本
- MAP.3随机安慰剂对照试验评估依西美坦,受试者在入组时和6个月时完成绝经特异性生活质量问卷(MENQOL)。
- 采用多变量对数二项回归评估基线特征和MENQOL临床有意义恶化与1年时治疗中止的关联。
- 4501名受试者纳入本分析。
主要发现
- 724名(17%)在随机分组后第一年内中止治疗,其中依西美坦组19%、安慰剂组13%。
- 治疗开始6个月内,19%至35%的女性在MENQOL血管舒缩、性、躯体和社会心理领域出现临床有意义的恶化。
- 无论是否接受依西美坦,任一MENQOL领域恶化或尤其整体绝经特异性生活质量恶化与早期治疗中止相关(整体恶化RR 1.79,95%CI 1.53-2.10)。
- 分配至依西美坦组、有吸烟史和当前就业也显著与早期中止相关。
关键数值与推荐
- MENQOL整体恶化与早期治疗中止的相对风险为1.79(95%CI 1.53-2.10)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Aromatase inhibitors are established breast cancer chemoprevention interventions. However, nonadherence remains a significant challenge. We investigated the association between worsening menopause-specific quality of life, baseline participant characteristics, and early treatment discontinuation within the Mammary Prevention.3 (MAP.3) breast cancer prevention trial. Methods In the MAP.3 randomized, placebo-controlled trial evaluating exemestane, participants completed the Menopause-Specific Quality of Life Questionnaire (MENQOL) at entry and at 6 months. Multivariable log-binomial regression was used to assess the associations of baseline participant characteristics and clinically meaningful worsening in menopause-specific quality of life (QOL) with treatment discontinuation at 1 year. Results Of the 4,501 participants eligible for this analysis, 724 (17%) discontinued assigned treatment within the first year of random assignment of treatment (19% of the exemestane group and 13% of the placebo group). Between 19% and 35% of women experienced a clinically meaningful worsening in the vasomotor, sexual, physical, and psychosocial domains of the MENQOL within 6 months of treatment initiation. Regardless of receiving exemestane or not, experiencing a worsening in any MENQOL domain or, especially, overall menopause-specific QOL, was associated with early treatment discontinuation (relative risk, 1.79; 95% CI, 1.53 to 2.10 for overall worsening). Assignment to exemestane, having a smoking history, and current employment also were significantly associated with early discontinuation. Conclusion Negative changes in menopause-specific QOL influence a woman's decision to stop chemoprevention therapy. Attention to such symptoms may improve QOL and potentially improve chemoprevention adherence.
引用
- Meggetto O, Maunsell E, Chlebowski R, et al. Factors Associated With Early Discontinuation of Study Treatment in the Mammary Prevention.3 Breast Cancer Chemoprevention Trial. J Clin Oncol. 2017. PMID: 28068170. doi:10.1200/JCO.2016.68.8895
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。